SCHEMBL2931503

SCHEMBL2931503

CC(C)(C)c1ccccc1Nc1nc2ccc(C(=O)O)cc2[nH]1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.51
TDP1 Q9NUW8 2/20 0.50
POLB P06746 1/20 0.50
HSP90AA1 P07900 1/20 0.50
ESR2 Q92731 1/20 0.50
LMNA P02545 3/20 0.48
ABL1 P00519 3/20 0.48
ALDH1A1 P00352 2/20 0.48
CYP1A2 P05177 2/20 0.48
CYP2C9 P11712 2/20 0.48
HTT P42858 2/20 0.48
HIF1A Q16665 2/20 0.48
ABCC4 O15439 1/20 0.48
USP2 O75604 1/20 0.48
KDR P35968 1/20 0.48
HDAC6 Q9UBN7 2/20 0.47
RAF1 P04049 3/20 0.47
BRAF P15056 3/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
PIK3CA P42336 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2927124 0.88 SMN1; SMN2 (0.56) AKR1C3TDP1POLBHSP90AA1ESR2
SCHEMBL1306959 0.84 P2RY1 (0.54)
SCHEMBL2929624 0.82 ALDH1A1 (0.54) AKR1C3TDP1POLBHSP90AA1ESR2
SCHEMBL2934474 0.82 AKR1C3 (0.54) AKR1C3TDP1POLBHSP90AA1ESR2
SCHEMBL2931480 0.81 AKR1C3 (0.51) AKR1C3TDP1POLBHSP90AA1ESR2
SCHEMBL2927341 0.81 LMNA (0.65) AKR1C3TDP1POLBHSP90AA1ESR2
SCHEMBL2928349 0.81 HDAC6 (0.55) AKR1C3TDP1POLBHSP90AA1ESR2
SCHEMBL2930797 0.81 AKR1C3 (0.56) AKR1C3TDP1POLBHSP90AA1ESR2
SCHEMBL2930184 0.80 AKR1C3 (0.49) AKR1C3TDP1POLBHSP90AA1ESR2
SCHEMBL1964565 0.79 AKR1C3 (0.51) AKR1C3POLBUSP2HDAC6RAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8377983-B2 Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors TRANSTECH PHARMA, INC. (US) 2013-02-19 US disclosed
US-7820821-B2 Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors TRANSTECH PHARMA, INC. (US) 2010-10-26 US disclosed
US-20100152170-A1 Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors TRANSTECH PHARMA, INC. (US) 2010-06-17 US disclosed
US-20070219235-A1 Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors VTVX HOLDINGS I LLC 2007-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152170-A1 Benzazole Derivatives, Compositions, And Methods Of Use As Aurora Kinase Inhibitors AURKC, AURKA, AURKB AKR1C3 944/4885TDP1 871/4885POLB 1990/4885
US-20070219235-A1 Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors AURKC, AURKA, AURKB AKR1C3 944/4885TDP1 871/4885POLB 1990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.